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used for mortality and ANCOVA was used for LOS with con-
founding factors adjusted in the models. Adjusted factors
included patient demographics, hospital characteristics (bed size,
region, teaching and PCI annual volume), co-morbid conditions
(chronic obstructive pulmonary disease, peripheral vascular
disease, diabetes mellitus, malignancy, acute renal failure) and
severity. RESULTS: Patients treated with nesiritide had signiﬁ-
cantly higher average hospital charges vs. not treated ($48,493
vs. $27,315, t = 22.94, p < 0.001). No better outcomes were
observed in nesiritide treated patients measured by LOS (10.03
vs 6.54, t = 22.71, p < 0.001) and mortality (Chi = 2.94, p =
0.086). The increased LOS (p < 0.001) in nesiritide treated group
were supported by ANCOVA model with control for covariates
including severity, mortality and payor type. Further analysis in
mortality by using conditional logistic regression showed con-
sistent results. CONCLUSIONS: Patients treated with nesiritide
are associated with higher costs, LOS and were not found to
obtain a cost effective therapy during their hospital stay. To
conﬁrm the ﬁnding, further study in inpatient settings and more
efﬁcient methods e.g. propensity score analysis are suggested to
better control for inﬂuencing factors.
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CARDIOVASCULAR RISK PREDICTED BY ADHERENCE TO
STATINS IN A MEDICAID POPULATION
Shaya FT, Samant ND, El Khoury AC
University of Maryland, Baltimore, MD, USA
OBJECTIVES: To determine the impact of adherence to statin
therapy on the incidence of cardiovascular events in a Medicaid
managed care population. METHODS: Retrospective database
analysis of Maryland Medicaid medical and pharmacy claims for
the period January 1, 2001–December 31, 2003. Inclusion cri-
teria: Continuously enrolled patients older than 18 years who
had at least one prescription claim for any of the statins. Exclu-
sion criteria (to obtain incident cohort): Patients who had at least
a claim before July 1st, 2002. Non-adherence was deﬁned as a
failure to reﬁll a prescription claim. Logistic regression models
were built to determine the association of drug adherence
adjusted for age, gender, race, comorbidities (based on Charlson
Comorbidity Index) with cardiovascular events. RESULTS: Out
of a total of 1997 patients, most were females (61%), African
Americans (57%), and 60 years old or younger (70%). Based on
univariate analysis, persistent patients had a lower incidence of
cardiovascular events than non-persistent patients (19% vs.
32%), females a lower incidence than males (24% vs. 35%) and
African Americans a lower incidence than Caucasians (24% vs.
34%). In the logistic regression model adjusting for comorbidi-
ties and demographics, drug adherence (OR 0.460, 59% CI
0.357, 0.593), African American race (OR 0.596, 95%CI 0.485,
0.734), and male gender (OR 1.674, 95% CI 1.369, 2.047) were
signiﬁcantly associated with CV events. CONCLUSION: In this
Medicaid population of statin users, the incidence of cardiovas-
cular events is higher in males, Caucasians and in patients who
do not adhere to statin therapy. Risk management programs may
need to focus on drug adherence among statin users, as one of
the major modiﬁable factors to reduce cardiovascular events.
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LOSS OF COMBINED OPTIMAL LIPID VALUE ACHIEVEMENT
AND THE RISK OF CARDIOVASCULAR EVENTS
Charland SL1, Cziraky MJ2, Sarawate C2, Stanek EJ1
1Kos Pharmaceuticals, Inc, Cranbury, NJ, USA, 2HealthCore, Inc,
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OBJECTIVES: Achieving combined optimal lipid values (OLVs)
for LDL-C, HDL-C, and triglycerides (TG) is associated with
reduced cardiovascular events; however little is known about the
subsequent loss of OLV. This study evaluated the loss of OLV
and associated cardiovascular events in a managed care (MCO)
population. METHODS: Patients were selected from a 2.1
million record database based on: lipid panel between January
1, 2000 and December 1, 2001, no concomitant lipid therapy,
and continuous eligibility for 24 months. Patients were catego-
rized as 1°/2° prevention, male/female, and diabetes mellitus
(DM). Guidelines deﬁned OLVs: NCEP ATP III (1° and 2° pre-
vention, men), AHA (women), and ADA (DM). Combined OLV
achievement was determined, as were cardiovascular events
based on ICD-9/CPT codes. The association between loss of
combined OLV achievement and cardiovascular events was eval-
uated by multivariate logistic regression and calculated odds
ratios (OR). RESULTS: The study included 44,351 patients: 1°
prevention (23,403); 2° prevention (20,948); males (22,345);
females (22,006); and DM (8,164). Mean age was 64 ± 13 years,
with a follow-up of 30 ± 12 months. Baseline lipids (mg/dL):
total cholesterol 210 ± 40; LDL-C 131 ± 35; HDL-C 48 ± 14;
and, TG 159 ± 77. Baseline combined OLV was achieved in
8–13%, which increased to 17–21% during follow-up. There
were 10,899 cardiovascular events experienced in 6,722 patients.
Loss of combined OLV was associated with an increase in car-
diovascular events in the total population (OR 1.43, 95% CI,
1.30–1.57). Subgroups demonstrated a similar increase in events
(OR: 1.40 to 1.67; 95% CI, 1.28 to 1.88) except 1° prevention
(OR, 1.2; 95% CI, 1.0–1.3). CONCLUSION: Combined OLVs
were achieved by <25% of patients. Loss of combined OLV
achievement was associated with a signiﬁcant 40 to 67%
increase in cardiovascular event risk, excepting 1° prevention
patients. Maintaining combined OLV achievement has the poten-
tial to signiﬁcantly improve outcomes across a wide spectrum of
patients.
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PATIENT EDUCATION INITIATIVE IN A MANAGED CARE
SETTING
Hoffman L1, Pendergrass A1, Sarawate C2, Bullano M2
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2HealthCore, Inc, Wilmington, DE, USA
OBJECTIVES: Adverse drug events (ADEs) associated with war-
farin therapy result in signiﬁcant morbidity, mortality, and eco-
nomic costs. Previous studies have demonstrated that ADEs are
associated with a Prothrombin Time (PT) or International Nor-
malized Ratio (INR) value outside of the accepted therapeutic
range. The purpose of this study is to evaluate the effectiveness
of a mail-based warfarin education program in improving
member PT/INR values and reducing ADEs and medical and
pharmacy costs in a managed care setting. METHODS: A total
of 1401 members initiated on warfarin therapy were random-
ized to an intervention or control group. The intervention group
received a series of six educational letters, which included infor-
mation about warfarin, the importance of PT/INR testing, signs
and symptoms of supra- and sub-therapeutic PT/INR values, and
a reminder to schedule physician appointments. Members were
followed for a mean of 341.5 days after initiation of warfarin.
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Clinical outcomes included number of ADEs (deep vein throm-
bosis, pulmonary embolism, stroke, bleeding, or hemorrhage)
number of PT/INR measurements after warfarin initiation, and
proportion of time spent within PT/INR range. Economic out-
comes included health care utilization and medical or pharmacy
costs. RESULTS: The Incidence Rate Ratio (IRR) for all ADEs
after warfarin initiation was 0.55 (95% CI 0.44–0.68) for the
intervention group as compared to control. Number of strokes
(IRR 0.61, 95% CI 0.39–0.94) and number of bleeding episodes
(IRR 0.59, 95% CI 0.44–0.79) were also signiﬁcantly reduced
for the intervention group. Mean proportion of time within the
therapeutic PT/INR range was 37% in the intervention group
and 31% in the control group (P = 0.0003). Economic outcomes
were not signiﬁcantly different between groups. CONCLU-
SIONS: This mail-based warfarin education program is associ-
ated with a decreased number of ADEs and an increased
proportion of time within the therapeutic PT/INR range.
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ASSESSMENT OF THE EFFECTS OF ROFECOXIB, CELECOXIB
AND NAPROXEN ON BLOOD PRESSURE AND
CARDIOVASCULAR RISK:A RETROSPECTIVE CHART REVIEW
STUDY
Brown RR1, Olmon MA2, Estoup MW3
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Inc, Lake Oswego, OR, USA, 3Pﬁzer, Inc, Beaverton, OR, USA
OBJECTIVES: Study objectives were to assess the impact of 
celecoxib, rofecoxib, or naproxen on blood pressure and BP 
goal attainment in a veteran population. Secondary objectives
included assessment of associated cardiovascular risk, and
changes to other medications associated with study drug use.
METHODS: Computerized medical and prescription records
were used to identify 262 consecutive patients receiving a new
prescription for rofecoxib, celecoxib or naproxen, from January
2001 to October 2005. Data collected in eligible patients
included patient demographics; drug utilization information for
the study drug and concomitant antihypertensives; baseline and
follow-up laboratory and clinical data including BP, and lipid
panel information. Inclusion criteria included age >49, treatment
with study drug for at least two weeks (not PRN), and stabi-
lization of preexisting antihypertensives for at least 30 days, for
hypertensive patients. Exclusion criteria included lack of follow-
up information or death prior to study completion, and/or use
of any of the following: MAO-inhibitors; tricyclic antidepres-
sants; sympathomimetics; glucocorticoids; corticotropin;
cyclosporine; oral contraceptives; concomitant NSAID’s (includ-
ing >325mg/day of aspirin). Statistical analysis was conducted
using the Chi-square test for demographic data. Intra-group
comparisons were analyzed using the paired student’s t-test,
while intra-group differences were assessed by analysis of vari-
ance. RESULTS: Analysis revealed signiﬁcant BP reduction in
celecoxib patients (-7/-5mmHg, p < 0.01). BP change was not
observed in naproxen patients, while BP increase was observed
in rofecoxib patients (+5/+2mmHg, p < 0.05). A majority of cele-
coxib patients were switched from an alternate therapy (60%
from rofecoxib, 9% from NSAID), while only 29% and 12% of
rofecoxib and naproxen patients were switched. BP reduction
was associated with improvement in JNC-VII stage in 47% of
celecoxib patients (p < 0.01), who were hypertensive (BP >
140/90) at treatment onset (47.5%). CONCLUSION: Clinically
relevant BP reduction may be an additional beneﬁt of celecoxib
in hypertensive patients requiring treatment with NSAID.
CARDIOVASCULAR DISEASE—Cost Studies
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CLOPIDOGREL THERAPY AND HEALTH CARE COSTS
FOLLOWING AN ACUTE CORONARY SYNDROME EVENT
Shetty SS1, McCollam PL2, Gomez-Rey G1
1i3 Magniﬁ, An Ingenix Company, Eden Prairie, MN, USA, 2Eli Lilly and
Company, Indianapolis, IN, USA
The antiplatelet clopidogrel is widely recommended in acute
coronary syndrome (ACS), however, most cost evaluations of
this therapy originate from the clinical trial environment.
OBJECTIVES: This study compared medical costs in the usual
care setting between clopidogrel and non-clopidogrel recipients
following an ACS event. METHODS: Administrative claims
data from a large U.S. health plan (from Janaury 1, 2001–June
30, 2003) were used to identify patients with ACS by ICD-9
codes for unstable angina or acute myocardial infarction; the ﬁrst
diagnosis claim was the “index event.” Patient groups were those
who received clopidogrel ≤15 days of an index event versus those
who did not. They were observed 1-year before, and followed
up to 1-year after, the index event. The primary endpoint was
medical costs during follow-up. Propensity score matching was
used to identify closely matched patient groups. Controlling for
confounding demographic and clinical characteristics, patients
were matched based on propensity to receive clopidogrel. Due
to variable follow-up periods, censored regression analysis was
used to compare costs; step one used a logistic regression model
to estimate the probability of not being censored; step two used
the inverse of this probability as a weight in the generalized linear
model (GLM). RESULTS: Propensity score matching identiﬁed
2826 patients (1413 in each group). Mean age was 58 years;
68% were male. The logistic regression indicated clopidogrel
patients had shorter follow-up periods. The weighted GLM indi-
cated monthly follow-up cardiovascular costs were 53% lower
and monthly follow-up all medical costs were 56% lower, for
clopidogrel versus non-clopidogrel patients (p < 0.05 for all com-
parisons). CONCLUSION: Patients who received clopidogrel
≤15 days from an ACS event had lower follow-up medical costs
compared to patients who did not receive clopidogrel. These data
provide additional economic support in the usual care setting for
clopidogrel treatment after ACS.
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